| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Sotera Health Company$18.39
+0.92 (+5.27%)
Market Cap
4.47 B
EPS
0.41
P/E Ratio
38.17 $
Value Trade
37.60 M
SEC Financials
Q1 2026Dilution Risk
Revenue
280.05 M
Operating CF
29.43 M
Total Assets
3.24 B
Total Liabilities
2.61 B
Equity
622.50 M
D/E Ratio
12,345
1.89 %
Week
-2.49 %
1 Month
-9.64 %
3 Month
-0.7 %
6 Month
-34.37 %
5 Year
-42 %
All Time
Cash Data
Cash Position
314.15 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 5, 2026
Overview
Volume
3.60 M
52 Week Range
10.80 - 19.85
% held by Insiders
2.56 %
% held by Institutions
87.65 %
Enterprise Value
6.42 B
Total Shares
284.47 M
Short %
8.06 %
Float Shares
218.75 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SHC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SHC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SHCSotera Health Announces Secondary Offering of Common Stock
Sotera Health Company has announced a secondary offering of 31,838,253 shares of common stock, which are being sold by affiliates of Warburg Pincus LLC and GTCR LLC. The company itself will not be selling any shares or receiving any proceeds from this offering, as it will only cover associated expenses. Goldman Sachs & Co. LLC is serving as the underwriter for this transaction. The announcement emphasizes potential risks related to the offering that could affect shareholder value.
Read more →SHCSotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook
Sotera Health reported a strong financial performance for Q1 2026, with net revenues increasing by 10% year-over-year. The company achieved a net income of $27 million, a significant improvement from a loss in Q1 2025. Adjusted EBITDA also saw a 10.5% increase, and the company reaffirmed its full-year growth outlook. The positive results were driven by strong performance in its Sterigenics and Nordion segments.
Read more →SHCSotera Health Announces Leadership Transition
Sotera Health announced a leadership transition with Alton Shader set to become CEO on May 26, 2026, succeeding Michael B. Petras, Jr. Petras will assume the role of Executive Chairman and continue to guide the company. Shader, with extensive experience in the medical industry, aims to build on Sotera's success in providing critical healthcare services.
Read more →SHCSotera Health Announces First-Quarter 2026 Earnings Release Date
Sotera Health Company has announced that it will release its financial results for the first quarter of 2026 before the market opens on May 5, 2026. Following the announcement, management will conduct a conference call to discuss the operating and financial results at 9:00 a.m. EDT. The company continues to emphasize its commitment to providing essential sterilization solutions and advisory services to the healthcare sector.
Read more →SHCSotera Health Appoints Kenneth D. Krause to the Board of Directors
Sotera Health Company has appointed Kenneth D. Krause as an independent director to its Board of Directors, effective March 16, 2026. Krause brings over ten years of experience as a public company CFO and a strong background in strategy and financial governance. He will serve on the Audit and Litigation Committees. Additionally, Dean S. Mihas has resigned from the Board due to a reduction in the number of directors designated by certain stockholders, ending his service since October 2020.
Read more →SHCSotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook
Sotera Health Company reported a 4.6% increase in fourth-quarter 2025 net revenues, marking its 20th consecutive year of revenue growth. The company achieved a net income of $35 million for the quarter and $78 million for the full year, driven by strong demand for its sterilization and lab testing services. Looking ahead, Sotera Health is optimistic about its financial outlook for 2026.
Read more →SHCSotera Health Announces Fourth-Quarter and Full-Year 2025 Earnings Release Date
Sotera Health Company has announced the release date for its fourth-quarter and full-year 2025 earnings. The financial results will be available before the market opens on February 24, 2026, followed by a conference call at 9:00 a.m. ET to discuss the results. The event will be accessible via a live webcast.
Read more →SHCSotera Health Appoints Richard Kyle to the Board of Directors
Sotera Health has appointed Richard G. Kyle as an independent director on its Board of Directors. Kyle, who previously served as CEO of The Timken Company, brings extensive experience in global operations and financial management. He will also participate in the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee.
Read more →SHCSotera Health to Showcase Continued Revenue Growth and Strategic Value Creation at 44th Annual J.P. Morgan Healthcare Conference
Sotera Health Company (SHC) has announced its continued revenue growth trajectory at the 44th Annual J.P. Morgan Healthcare Conference, projecting revenue to exceed $1.16 billion for 2025, marking at least a 5.5% increase year over year. The company's Chairman and CEO emphasized their strong business model and commitment to customer excellence, reflecting two decades of revenue growth. Full-year financial results and outlook for 2026 will be shared on February 24, 2026. Sotera Health operates through three key businesses: Sterigenics, Nordion, and Nelson Labs.
Read more →SHCSotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sotera Health Company announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2026. The company's management will present at 1:30 p.m. ET and will also hold investor meetings. A live webcast of the presentation will be available on their website, with a replay accessible within 48 hours.
Read more →SHCcould adversely affect our ability to raise additional capital, limit our ability to react to challenges confronting our Company or broader changes in our industry or the economy, limit our flexibility in operating our b
Sotera Health Company presented a positive outlook at the 44th Annual J.P. Morgan Healthcare Conference, projecting 2025 revenue to exceed $1.16 billion, marking over 20 years of growth. CEO Michael B. Petras, Jr. emphasized the company's robust financial position and commitment to customer service. However, the company faces several risks, including potential supply chain disruptions and ongoing legal challenges that could affect financial stability. The full-year results and future outlook are set to be discussed on February 24, 2026.
Read more →SHCSotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Results
Sotera Health Company reported robust financial results for Q3 and year-to-date 2025, with net revenues rising by 9.1% to $311 million and net income increasing significantly. The company achieved double-digit growth in Adjusted EBITDA and reaffirmed its revenue outlook for the year while raising its Adjusted EBITDA forecast. However, pending settlements related to ethylene oxide claims pose potential risks.
Read more →SHCSotera Health Announces Third-Quarter 2025 Earnings Release Date
Sotera Health Company has announced the date for its third-quarter 2025 earnings release, scheduled for November 4, 2025. The company will provide financial results for the quarter ended September 30, 2025, before the market opens. Following the release, a conference call will be held to discuss the results and highlights.
Read more →SHC▲ +24.5%on this news· ran to +40% by day 3
Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis (1) , compared to Q2 2024 Q2 2025 net income of $8 million
Sotera Health Company (SHC) reported strong financial results for the second quarter and first half of 2025, with a 6.4% rise in net revenues to $294 million and a notable increase in Adjusted EBITDA by nearly 10%. Despite a decrease in net income due to ongoing ethylene oxide claims settlements, the company raised its full-year outlook for revenue and Adjusted EBITDA, indicating a positive trend in performance. The company highlighted robust growth driven by Sterigenics, although some challenges were noted in the Nordion and Nelson Labs segments.
Read more →SHCSotera Health Announces Second-Quarter 2025 Earnings Release Date
Sotera Health Company announced that it will release its financial results for the second quarter of 2025 on August 8, 2025. Following the earnings release, management will host a conference call at 9:00 a.m. EDT to discuss the results and operating highlights. Investors can participate by phone or access a live webcast via the company's website, with a replay available later that day.
Read more →SHC▲ +5.2%on this news
Sotera Health Reports First-Quarter 2025 Results
Sotera Health Company reported its first-quarter 2025 financial results, revealing a 2.6% increase in net revenues to $255 million compared to the previous year, despite reporting a net loss of $13 million. Adjusted EBITDA rose by 8.8%, reflecting strong operational performance. The company reaffirmed its full-year outlook, projecting net revenue growth of 4.0% to 6.0% and Adjusted EBITDA growth of 4.5% to 6.5%. However, the results were impacted by a pending settlement related to ethylene oxide claims, raising concerns among investors.
Read more →SHC▲ +5.2%on this news
Sotera Health Reports First-Quarter 2025 Results Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basis Q1 2025 net loss of $13 million or $0.05 per diluted share,
Sotera Health reported its Q1 2025 financial results, noting a 2.6% increase in net revenues year-over-year to $255 million. Despite this revenue growth, the company experienced a net loss of $13 million for the quarter, significantly down from a profit of $6 million in the previous year. Adjusted EBITDA improved by 8.8%, supporting ongoing operational efficiency. The company reaffirmed its full-year outlook, projecting continued growth in both revenues and EBITDA.
Read more →SHCSotera Health Announces First-Quarter 2025 Earnings Release Date
Sotera Health Company has announced the release date for its first-quarter 2025 earnings, scheduled for May 1, 2025, before market opening. The company, known for its sterilization solutions, will hold a conference call the same day at 9:00 a.m. EDT to discuss its financial results and operational highlights. Investors can participate via a toll-free call or through a live webcast, with a replay available afterward.
Read more →SHC▼ -10%on this news
Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results Provides 2025 Outlook 2024 net revenues increased 4.9% to $1.10 billion , compared to 2023 or 5.4% on a constant currency basis 2024 net income of $44 milli
Sotera Health reported its financial results for the fourth quarter and full year of 2024, showing a 4.9% increase in net revenues to $1.10 billion. Despite an overall positive performance this year, the fourth quarter saw a drop in revenues by 6.5%, attributed to specific market conditions and segment performance variations. The company also provided an outlook for 2025, projecting 4.0% to 6.0% growth in net revenues and 4.5% to 6.5% growth in Adjusted EBITDA, acknowledging challenges related to foreign currency impacts.
Read more →SHCSotera Health Announces Fourth-Quarter and Full-Year 2024 Earnings Release Date
Sotera Health Company (Nasdaq: SHC) announced it will release its financial results for the fourth quarter and full year ended December 31, 2024, on February 27, 2025, before the market opens. The company will host a conference call at 9:00 a.m. Eastern Time to discuss these results and operational highlights. Stakeholders can access the call via a dedicated phone line or through a live webcast on the company's Investor Relations webpage. Additionally, Sotera Health underscores its commitment to global health through its sterilization and lab testing services.
Read more →SHCSotera Health Chairman and CEO Presents at 43rd Annual J.P. Morgan Healthcare Conference CLEVELAND, OH
Sotera Health Company presented at the 43rd Annual J.P. Morgan Healthcare Conference, where CEO Michael B. Petras Jr. reported a strong top-line growth for 2024, with expected revenues around $1.1 billion, marking nearly 5% growth compared to the previous year. The resilience of Sotera Health's business model was highlighted, allowing for service excellence under diverse market conditions. However, the company cautioned that actual financial outcomes may differ from estimates due to ongoing financial closing procedures and possible legal risks associated with operational emissions.
Read more →SHCSotera Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Sotera Health Company, a global leader in sterilization solutions and lab testing services, announced that its Chairman and CEO, Michael B. Petras, Jr., will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. Along with him, key executives will be participating in investor meetings during the event. A live webcast of the presentation will be available on the company's Investor Relations website, with a replay accessible afterward.
Read more →SHCSotera Health Company Appoints Vincent K. Petrella as Lead Independent Director CLEVELAND, OH
Sotera Health Company has appointed Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Petrella, who has been on the Board since 2020, will enhance governance as a key liaison between management and shareholders. His extensive experience includes roles in public company leadership and finance, and he has expressed enthusiasm for his expanded responsibilities. This appointment is seen as a strategic move to bolster the company’s leadership.
Read more →SHCSotera Health to Share Next Chapter of Growth at 2024 Investor Day CLEVELAND, OH
Sotera Health Company (Nasdaq: SHC) will hold its inaugural Investor Day in New York City, where the management team will outline the company's growth strategy. Since going public in 2020, Sotera has experienced strong financial performance, characterized by growth in revenues and profitability. CEO Michael J. Petras, Jr. expressed pride in the company's achievements and highlighted durable customer relationships as part of their ongoing success. The event will include a live question-and-answer session for audience engagement.
Read more →SHCSotera Health Reports Third-Quarter and Year-to-Date 2024 Results Q3 2024 net revenues of $285 million increased 8.5%, compared to Q3 2023 Q3 2024 net income of $17 million or $0.06 per diluted share, compared to net los
Sotera Health reported strong financial results for Q3 2024, with net revenues reaching $285 million, reflecting an 8.5% increase year-over-year. The company also achieved net income of $17 million, a significant rebound from a previous loss of $14 million. Adjusted EBITDA and Adjusted EPS also showed healthy growth, affirming the company's positive outlook for the year. Sotera Health's management is set to present future growth plans during their upcoming investor day event on November 20th.
Read more →SHCSotera Health Announces Dates for Third-Quarter 2024 Earnings Release and November 2024 Investor Day
Sotera Health Company (Nasdaq: SHC) announced its financial results release for Q3 2024, scheduled for November 5, 2024. Following the earnings announcement, management will host a conference call to discuss operational highlights. Additionally, Sotera Health will hold its first Investor Day on November 20, 2024, in New York City, providing insights from its management team. Both events emphasize the company's focus on transparency and investor relations.
Read more →SHC▲ +7.6%on this news
Sotera Health Reports Second-Quarter and First-Half 2024 Results Q2 2024 net revenues of $277 million increased 8%, compared to Q2 2023 Q2 2024 net income of $9 million or $0.03 per diluted share, compared to net income
Sotera Health Company reported financial results for Q2 and the first half of 2024, featuring an 8.3% increase in net revenues to $277 million compared to the same period in 2023. However, net income decreased to $9 million, largely due to refinancing costs, while adjusted EPS saw a minor dip. The company successfully refinanced its debt, extending maturities to 2031 and reaffirmed its 2024 financial outlook, expecting revenue and adjusted EBITDA growth of 4-6%. Despite positive revenue growth across all business segments, rising interest expenses affected overall profitability.
Read more →SHCSotera Health Appoints Christopher Simon to the Board of Directors
Sotera Health Company has appointed Christopher Simon as an independent director on its Board of Directors. With over 30 years of experience in the life sciences sector, Simon has previously served as the CEO of Haemonetics Corporation and held senior roles at McKinsey & Company and Baxter Healthcare. His extensive leadership background is expected to significantly contribute to Sotera's ongoing growth. Simon also serves on the board of AdvaMed, highlighting his engagement in the medical technology field.
Read more →SHCSotera Health Announces Second-Quarter 2024 Earnings Release Date
Sotera Health Company has announced the date for its second-quarter 2024 earnings release, which is set for August 5, 2024. The company will conduct a conference call to discuss its financial results and operating highlights. Participants can join the call via provided phone numbers or access a live webcast. Sotera Health continues to position itself as a significant player in the healthcare sterilization and lab testing markets.
Read more →SHCSotera Health Announces Closing of $1.5 Billion Term Loan B and $750 Million Senior Secured Note Financings
Sotera Health Company has successfully closed a new $1.5 billion Term Loan B and issued $750 million in senior secured notes, both maturing in 2031. The funds will be used to refinance existing debt and are expected to yield approximately $5 million in interest expense savings for 2024. This refinancing is viewed positively, reflecting strong market confidence in the company's capabilities. However, the company faces forward-looking risks including potential supply disruptions and ongoing legal challenges regarding regulatory compliance.
Read more →SHCSotera Health Reports First-Quarter 2024 Results
Sotera Health Company reported a strong financial performance for Q1 2024, with net revenues increasing by 12.5% to $248 million year-over-year. Net income also rose to $6 million, reflecting a solid start to the year. The company reaffirmed its 2024 outlook despite ongoing market challenges, particularly the strict new emissions standards from the EPA, which may impact compliance for the sterilization industry. Overall, Sotera remains focused on its strategic priorities and supporting its workforce and customers.
Read more →SHCSotera Health Reports First-Quarter 2024 Results Q1 2024 net revenues increased 12.5% to $248 million, compared to Q1 2023 Q1 2024 net income of $6 million or $0.02 per diluted share, comp ared to net income of $3 millio
Sotera Health reported a strong first quarter for 2024, with net revenues of $248 million, marking a 12.5% increase from the previous year. Net income also saw significant growth, reaching $6 million compared to $3 million in Q1 2023. The company has reaffirmed its 2024 outlook, indicating expectations for further growth, although it acknowledged potential challenges related to regulatory standards in the sterilization industry. The positive performance reflects effective strategic execution amidst market headwinds.
Read more →SHCSotera Health Announces First-Quarter 2024 Earnings Release Date
Sotera Health Company has announced it will release its financial results for the first quarter of 2024 on May 2, 2024, before the market opens. Following the release, management will conduct a conference call at 9:00 a.m. Eastern Time to discuss the results and highlight key operational developments. Investors can participate in the call via telephone or access a live webcast on the company's website. The company remains focused on its mission to provide crucial sterilization and lab testing services for the healthcare industry.
Read more →SHC▼ -13.8%on this news
Sotera Health Announces Pricing of Secondary Offering
Sotera Health Company has announced the pricing of its secondary offering of 25,000,000 shares at $14.75 per share, with no proceeds going to the company. The offering will close on March 4, 2024, pending customary closing conditions. Notable investors such as Warburg Pincus LLC and GTCR LLC are involved as selling stockholders. The offering will be managed by major financial institutions including J.P. Morgan and Goldman Sachs.
Read more →SHCSotera Health Reports Fourth-Quarter and Full-Year 2023 Results Provides 2024 Outlook 2023 net revenues increased 4.5% to $1.05 billion , compared to 2022 2023 net income of $51 million or $0.18 per diluted share 2023 Ad
Sotera Health (SHC) reported its financial results for 2023, highlighting a 4.5% increase in net revenues to $1.05 billion. The fourth-quarter results showed a significant quarterly growth of 23.3% in net revenues. However, adjusted EPS decreased by $0.15 from the previous year. The company also provided a positive outlook for 2024, projecting growth in net revenues and adjusted EBITDA between 4.0% and 6.0%. Despite an increase in total debt, the strong revenue growth indicates resilience in the current market conditions.
Read more →SHCSotera Health Announces Fourth-Quarter and Full-Year 2023 Earnings Release Date
Sotera Health Company (Nasdaq: SHC) is set to release its financial results for the fourth quarter and full year ending December 31, 2023, on February 27, 2024. A conference call will follow the release at 9:00 a.m. ET to discuss the operating highlights and financial performance. The company is recognized for its comprehensive sterilization solutions and lab testing services for the healthcare sector.
Read more →SHCSotera Health Chairman and CEO Presents at 42nd Annual J.P. Morgan Healthcare Conference
Sotera Health Company is presenting at the 42nd Annual J.P. Morgan Healthcare Conference, where Chairman and CEO Michael B. Petras, Jr. will discuss the company's updates. Sotera Health is expected to achieve revenues between $1.040 billion and $1.050 billion in 2023, showcasing consistent growth since going public in 2020. The company is aware of various risks, including legal challenges and potential supply disruptions for critical materials, but remains committed to its mission in global healthcare.
Read more →SHCSotera Health Chairman and CEO Presents at 42 nd Annual J.P. Morgan Healthcare Conference CLEVELAND, OH
Sotera Health Company, represented by Chairman and CEO Michael B. Petras, Jr., presented at the 42nd Annual J.P. Morgan Healthcare Conference. The company reported achieving significant top-line growth in 2023, expecting revenues between $1.040 billion and $1.050 billion. Management emphasized the company's resilience and its critical role in global healthcare, alongside announcing a forthcoming report on their financial results for 2023. Sotera operates through its Sterigenics, Nordion, and Nelson Labs divisions, focusing on sterilization solutions and lab testing for the healthcare sector.
Read more →SHCSotera Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Sotera Health Company, a leading provider of sterilization solutions, announced that Chairman and CEO Michael B. Petras, Jr. will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. Alongside him, Senior Vice President and CFO Jon Lyons, and Vice President and Treasurer Jason Peterson will engage in investor meetings during the event. A live webcast of the presentation will be available on the company's website, and a replay will be archived for later access.
Read more →SHCSotera Health Reports Third-Quarter and Year-to-Date 2023 Results Q3 2023 net revenues of $263 million increased 6%, compared to Q3 2022 Q3 2023 net loss of $14 million or $0.05 per diluted share, compared to net income
Sotera Health reported its financial results for the third quarter and nine months ending September 30, 2023. While net revenues for Q3 increased by 6% to $263 million, the company experienced a net loss of $14 million, contrasting sharply with the $25 million net income from the same period last year. Adjusted EBITDA showed a positive trend, rising by 7% to $134 million. However, the company also acknowledges ongoing market challenges and reaffirms a cautious outlook for the remainder of 2023.
Read more →SHCSotera Health Reports Second-Quarter and First-Half 2023 Results Q2 2023 net revenues of $255 million decreased 4%, compared to Q2 2022, primarily driven by expected Nordion Cobalt-60 harvest schedule timing Q2 2023 net
Sotera Health reported a decline in financial performance for Q2 and the first half of 2023, with net revenues decreasing 4.3% year-over-year. The company adjusted its full-year revenue outlook down to between $1.035 billion and $1.055 billion, citing volume softness and timing of Cobalt-60 supplies as key factors. While some business segments like Sterigenics showed growth, others such as Nordion faced significant revenue declines. Sotera Health also highlights a successful litigation settlement and margin improvements in certain units.
Read more →SHCDocument Sotera Health Announces Jon Lyons as New Senior Vice President and Chief Financial Officer CLEVELAND, OH
Sotera Health Company has appointed Jon Lyons as its new Senior Vice President and Chief Financial Officer, effective immediately. Lyons previously held significant finance positions at Owens Corning and Cardinal Health, bringing a wealth of expertise to the role. He will be an integral part of the executive team, reporting directly to CEO Michael B. Petras, Jr. and aims to enhance Sotera Health's mission of safeguarding global health.
Read more →SHCSOTERA HEALTH INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sotera Health Company - SHC
Kahn Swick & Foti, LLC has initiated an investigation into Sotera Health Company following a jury's verdict holding the company liable for misconduct related to toxic EtO emissions. This investigation aims to determine if the company's officers and directors violated their fiduciary duties or breached any laws. Additionally, Sotera is currently facing a securities class action lawsuit that accuses its executives of failing to disclose critical information during the relevant period, raising serious legal and reputational concerns for the company.
Read more →SHCSotera Health Company (SHC) Stock News: Robbins LLP is Investigating the Officers and Directors of Sotera Health Company on Behalf of Investors
Robbins LLP has launched an investigation into Sotera Health Company and its management regarding potential violations of securities laws related to the company's public offerings. This comes on the heels of serious allegations regarding its EtO sterilization process, which has been linked to cancer rates in communities near its facilities. The company's previous claims about emissions control and safety measures have come under scrutiny, especially following a significant legal judgment against it for health risks caused by toxic emissions. As a result, Sotera's stock has faced a steep decline and significant downgrades from analysts.
Read more →SHC▼ -5.1%on this news
Sotera Health Reports First-Quarter 2023 Results Q1 2023 net revenues of $221 million decreased 7%, compared to Q1 2022, primarily driven by Nordion Cobalt-60 harvest schedule timing, as expected Q1 2023 net income of $3
Sotera Health reported a decrease in net revenues for Q1 2023, amounting to $221 million, a 7% decline from the previous year, primarily due to the timing of Nordion's Cobalt-60 harvest. Net income also fell sharply to $3 million, down from $31 million a year earlier. Despite these challenges, the company reaffirmed its 2023 revenue growth outlook of 5%-9%, attributing anticipated improvements to other segments later in the year. Notably, the Sterigenics segment performed well with a 7% revenue increase compared to the prior year, countering some revenue declines from other areas.
Read more →SHCSOTERA HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Sotera Health Company - SHC
NEW ORLEANS, March 21, 2023 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 27, 2023 to file lead plaintiff applications in a securities class action lawsui
Read more →SHCSotera Health Amends and Upsizes Revolving Credit Facility CLEVELAND, OH
Sotera Health Company announced a successful amendment to its First Lien Credit Agreement, increasing the total available commitments under its revolving credit facility from $347.5 million to $423.8 million. The amendment also raises lender commitments for letters of credit from approximately $196 million to $361 million. This move is seen as a strong indication of Sotera Health's robust cash-generating profile and solid relationships with lenders, while the company currently does not expect any borrowings under the facility.
Read more →SHCSOTERA HEALTH COMPANY (NASDAQ: SHC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Sotera Health Company (NASDAQ: SHC)
Did you lose money on investments in Sotera Health? If so, please visit Sotera Health Company Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. NEW YORK, March 20, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebh
Read more →SHCSOTERA HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Sotera Health Company - SHC
NEW ORLEANS, March 14, 2023 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 27, 2023 to file lead plaintiff applications in a securities class action lawsuit against Sotera Health Company (NasdaqGS: SHC), if th
Read more →SHCSotera Health Reports Fourth-Quarter and Full-Year 2022 Results Provides 2023 Outlook Q4 2022 net revenues increased 4% to $252 million, compared to Q4 2021 Q4 2022 net loss of $320 million or $1.14 per diluted share, wh
Sotera Health reported a 4% increase in net revenues for Q4 2022, but also a substantial net loss of $320 million, largely due to a legal reserve. For the full year, the company experienced a net loss of $234 million, as opposed to a profit in the previous year. Despite these setbacks, Sotera projected a positive outlook for 2023, anticipating net revenue growth of 5% to 9%, alongside an increase in Adjusted EBITDA. The company is committing to ongoing capacity expansions and operational excellence initiatives while navigating macroeconomic and supply chain challenges.
Read more →SHCSotera Health Closes on $500 Million Term Loan B Financing CLEVELAND, OH
Sotera Health Company announced the successful closure of a $500 million senior secured Term Loan B financing. The funds will be used primarily to address a substantial litigation settlement and enhance liquidity. The loan attracted a positive market reception, reflecting confidence in the company's business model. However, the company remains exposed to litigation risks which could impact its financial condition.
Read more →SHCSotera Health Company: Please contact the Portnoy Law Firm to recover your losses; March 27, 2023 deadline
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 16, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sotera Health Company (“Sotera” or “the Company”) (NASDAQ: SHC) investors that a lawsuit filed on behalf of inve
Read more →SHCSotera Health Company (SHC) Class Action Alert: Robbins LLP Urges Shareholders to Contact the Firm Regarding Representation in the Class Action Against Sotera Health Company
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Sotera Health Company (NASDAQ: SHC) common stock: (i) pursuant to the Company's initial pu
Read more →SHCSotera Health Confirms Preliminary 2022 Full-Year Guidance in Conjunction with Incremental Debt Financing Cleveland, Ohio
Sotera Health Company has confirmed its preliminary 2022 financial guidance while announcing plans for a $425 million debt financing. The company estimates its full-year net revenues will remain within the previously announced range of $995 million to $1.005 billion but expects a notable net loss between $226 million and $236 million due to a legal reserve for an ethylene oxide litigation settlement. Final financial results will be reported on February 28, 2023, but current estimates may face substantial revisions as management finalizes the details.
Read more →SHCSotera Health Company (SHC) Class Action Alert: Contact Robbins LLP for Information Regarding the Class Action Against Sotera Health Company
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Sotera Health Company (NASDAQ: SHC) common stock: (i) pursuant to the Company's initial pu
Read more →SHCSOTERA HEALTH COMPANY INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Sotera Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Sotera Health Company (“Sotera” or the “Company”) (NASDAQ: SHC). A complaint has been filed on behalf of investors who purchased or otherw
Read more →SHCSOTERA HEALTH COMPANY (NASDAQ: SHC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Sotera Health Company (NASDAQ: SHC)
Did you lose money on investments in Sotera Health? If so, please visit Sotera Health Company Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebha
Read more →SHCDocument Sotera Health Chairman and CEO Presents at 41 st Annual J.P. Morgan Healthcare Conference CLEVELAND, OH
Sotera Health Company presented at the 41st Annual J.P. Morgan Healthcare Conference, highlighting solid revenue growth for 2022. CEO Michael B. Petras Jr. shared that the company's expected revenues are in the range of $995 million to $1.005 billion. However, the company is considering additional debt financing due to ongoing litigation that may affect financial stability. Investors can access the presentation through the company's website's Investor Relations section.
Read more →SHCDocument Sotera Health Announces Settlement of Ethylene Oxide Litigation in Illinois Settlement Explicitly Does Not Constitute Admission of Liability CLEVELAND, OH
Sotera Health Company has announced a settlement agreement concerning over 870 ethylene oxide cases in Illinois, with Sterigenics agreeing to pay $408 million. The settlement does not imply admission of liability, as both companies maintain their operations did not pose safety risks. The administration of the settlement is anticipated to take 90 to 120 days and hinges on the cooperation of plaintiffs. Additionally, Sotera Health will pursue incremental debt financing to address the settlement expense, highlighting potential financial implications and uncertainty regarding future claims.
Read more →SHC▼ -8.7%on this news
Sotera Health Reports Third-Quarter and Year-to-Date 2022 Results Q3 2022 net revenues of $249 million increased 10%, compared to Q3 2021 Q3 2022 net income of $25 million or $0.09 per diluted share, compared to net inco
Sotera Health Reports Third-Quarter and Year-to-Date 2022 Results Q3 2022 net revenues of $249 million increased 10%, compared to Q3 2021 Q3 2022 net income of $25 million or $0.09 per diluted share, compared to net income of $27 million or $0.10 per diluted share in Q3 2021 Q
Read more →SHCSotera Health Reports Second-Quarter and First-Half 2022 Results Q2 2022 net revenues of $267 million increased 6%, compared to Q2 2021 Q2 2022 net income of $30 million or $0.11 per diluted share, compared to net income
Sotera Health Reports Second-Quarter and First-Half 2022 Results Q2 2022 net revenues of $267 million increased 6%, compared to Q2 2021 Q2 2022 net income of $30 million or $0.11 per diluted share, compared to net income of $43 million or $0.15 per diluted share in Q2 2021 Q2
Read more →SHCSotera Health Announces Second-Quarter 2022 Earnings Release Date Names Michael F. Biehl as Interim Chief Financial Officer CLEVELAND, OH
Sotera Health Announces Second-Quarter 2022 Earnings Release Date Names Michael F. Biehl as Interim Chief Financial Officer CLEVELAND, OH, July 20, 2022 (GLOBE NEWSWIRE) Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization
Read more →SHCSotera Health Announces Departure of Chief Financial Officer Scott Leffler
Sotera Health Announces Departure of Chief Financial Officer Scott Leffler CLEVELAND, Ohio, May 19, 2022 Sotera Health Company (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcar
Read more →SHCSotera Health Reports First-Quarter 2022 Results Q1 2022 net revenues of $237 million increased 12%, compared to Q1 2021 Q1 2022 net income of $31 million or $0.11 per diluted share, compared to net income of $11 million
Sotera Health Reports First-Quarter 2022 Results Q1 2022 net revenues of $237 million increased 12%, compared to Q1 2021 Q1 2022 net income of $31 million or $0.11 per diluted share, compared to net income of $11 million or $0.04 per diluted share in Q1 2021 Q1 2022 Adjusted E
Read more →SHCSotera Health Reports Fourth-Quarter and Full-Year 2021 Results Provides 2022 Outlook Q4 2021 net revenues increased 11% to $241 million, compared to Q4 2020 Q4 2021 net income of $36 million or $0.13 per diluted share,
Sotera Health Reports Fourth-Quarter and Full-Year 2021 Results Provides 2022 Outlook Q4 2021 net revenues increased 11% to $241 million, compared to Q4 2020 Q4 2021 net income of $36 million or $0.13 per diluted share, compared to a net loss of $44 million or $(0.17) per dilu
Read more →SHC▼ -10.8%on this news
Sotera Health Reports Third-Quarter and Year-to-Date 2021 Results Q3 2021 net revenues of $226 million increased 13%, compared to Q3 2020 Q3 2021 net income of $27 million or $0.10 per diluted share, compared to net inco
Sotera Health Reports Third-Quarter and Year-to-Date 2021 Results Q3 2021 net revenues of $226 million increased 13%, compared to Q3 2020 Q3 2021 net income of $27 million or $0.10 per diluted share, compared to net income of $0.01 million or $0.00 per diluted share in Q3 2020
Read more →SHCSotera Health Reports Second-Quarter and First-Half 2021 Results Increases 2021 Outlook Q2 2021 net revenues of $252 million increased approximately 18%, compared to Q2 2020 Q2 2021 net income of $43 million or $0.15 per
Sotera Health Reports Second-Quarter and First-Half 2021 Results Increases 2021 Outlook Q2 2021 net revenues of $252 million increased approximately 18%, compared to Q2 2020 Q2 2021 net income of $43 million or $0.15 per diluted share, compared to net income of $7 million or $0
Read more →SHCSotera Health Reports First-Quarter 2021 Results Q1 2021 net revenues of $212 million increased 13%, compared to Q1 2020 Q1 2021 net income of $11 million or $0.04 per diluted share, compared to a net loss of $2 million
Sotera Health Reports First-Quarter 2021 Results Q1 2021 net revenues of $212 million increased 13%, compared to Q1 2020 Q1 2021 net income of $11 million or $0.04 per diluted share, compared to a net loss of $2 million or $0.01 per diluted share in Q1 2020 Q1 2021 includes $14
Read more →SHCSotera Health Reports Fourth-Quarter and Full-Year 2020 Results Provides 2021 Outlook Q4 2020 net revenues of $217 million increased 12%, compared to Q4 2019 Q4 2020 net loss of $44 million or $0.17 per diluted share, co
Sotera Health Reports Fourth-Quarter and Full-Year 2020 Results Provides 2021 Outlook Q4 2020 net revenues of $217 million increased 12%, compared to Q4 2019 Q4 2020 net loss of $44 million or $0.17 per diluted share, compared to a net loss of $28 million or $0.12 per diluted
Read more →SHCSotera Health Announces Successful Repricing of its First Lien Term Loan Facility CLEVELAND, OH
Sotera Health Announces Successful Repricing of its First Lien Term Loan Facility CLEVELAND, OH, Jan. 20, 2021 - Sotera Health Company (Nasdaq SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the he
Read more →SHCSotera Health Announces Preliminary Fourth-Quarter and Full-Year 2020 Revenue CLEVELAND, OH
Sotera Health Announces Preliminary Fourth-Quarter and Full-Year 2020 Revenue CLEVELAND, OH, Jan. 11, 2021 - Sotera Health Company (Nasdaq SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the health
Read more →SHCSotera Health Announces Debt Pay Down and Expansion of Revolving Credit Facility CLEVELAND
Sotera Health Announces Debt Pay Down and Expansion of Revolving Credit Facility CLEVELAND, Dec. 18, 2020 (GLOBE NEWSWIRE) Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services
Read more →SHCSotera Wireless Joins NPSF Patient Safety Coalition
BOSTON, MASS., June 30, 2015 (GLOBE NEWSWIRE) -- The National Patient Safety Foundation (NPSF), a central voice for patient safety since 1997, recently welcomed Sotera Wireless as a member of the NPSF Patient Safety Coalition. Sotera Wireless, based in San Diego, California, spe
Read more →Competitive Position
How SHC ranks across every disease it competes inCompetitive Position is a premium feature
See how SHC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial